Monopar Therapeutics develops pharmaceutical drug candidates for Wilson disease and radiopharmaceutical cancer treatment. MNPR reports earnings on Thu, Nov 12, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Prices, price targets and earnings estimates for MNPR are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in MNPR in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNPR is in one of them and how their past MNPR trades turned out.
Monopar Therapeutics is a pharmaceutical company based in Wilmette, Illinois, that develops drug candidates. Its candidates include ALXN1840, licensed from AstraZeneca and in development for Wilson disease, and MNPR-101, which is being developed for radiopharmaceutical use in cancer treatment. The company relies on patents and licensed intellectual property to protect these candidates.
